Vymedic
Scientifically proven broad-spectrum antiviral beats industry-leading treatments in the suppression of flu, colds and common viruses.
Overview
Raised: $202,770
Rolling Commitments ($USD)
03/30/2021
$1,127
2020
Healthcare & Pharmaceuticals
Biotech
B2C
High
High
Summary Profit and Loss Statement
Most Recent Year | Prior Year | |
---|---|---|
Revenue |
$0 |
$0 |
COGS |
$0 |
$0 |
Tax |
$0 |
$0 |
| ||
| ||
Net Income |
$-46,788 |
$-45,688 |
Summary Balance Sheet
Most Recent Year | Prior Year | |
---|---|---|
Cash |
$2,032 |
$3,105 |
Accounts Receivable |
$0 |
$0 |
Total Assets |
$2,032 |
$3,105 |
Short-Term Debt |
$0 |
$0 |
Long-Term Debt |
$0 |
$0 |
Total Liabilities |
$0 |
$0 |
Upgrade to gain access
-
$25 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific KingsCrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Founder Profile
Vymedic Founder Cynthia Winning on Antiviral Solutions
In the age of COVID-19, broad-spectrum, OTC, antivirals could change the game. Under the leadership of Cynthia Winning, the team at Vymedic is aiming to disrupt the OTC wellness space with a new immune support tablet. We sat down with Cynthia to discuss what inspired her to build the company, her vision for the future of the space, and more-